Article

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

2022-07-22

Abstract excerpt

<title>Abstract</title> <p>Background Although Immune checkpoint inhibitors (ICIs) associated liver damage usually presented as mild elevations of liver enzymes, hepatic failure induced by ICIs have been reported in only a few case series and case reports. Objective We aimed to explore the association between ICIs and hepatic failure, and characterize the clinical features of ICI-associated hepatic failure in t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 02dec7ab-3c81-5ee3-86d8-c3070a082ea0
DOI: 10.21203/rs.3.rs-1855307/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseDOI 10.21203/rs.3.rs-1855307/v1Read

Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.Semantic proximity Read

Application of Tocilizumab in Drug-Induced Liver Injury: Pharmacovigilance Study Using the FAERS Database and the Drug-Gene Interaction Network AnalysisSemantic proximity Read

Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors.Semantic proximity Read

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver diseaseSemantic proximity Read

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in PolandSemantic proximity Read

Investigation of tazobactam/piperacillin– or meropenem–induced liver injury based on retrospective observational study and the FDA Adverse Event Reporting SystemSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Baseline risk factors associated with immune related adverse events and atezolizumabSemantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.Semantic proximity Read

Drug-induced liver injury: a safety review.Semantic proximity Read